Literature DB >> 15163715

Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle.

Jean-François Giguère1, Salim Bounou, Jean-Sébastien Paquette, Joaquín Madrenas, Michel J Tremblay.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) carries virus-encoded and host-derived proteins. Recent advances in the functional characterization of host molecules inserted into mature virus particles have revealed that HIV-1 biology is influenced by the acquisition of host cell membrane components. The CD28/B7 receptor/ligand system is considered one of the fundamental elements of the normal immune response. Two major cell types that harbor HIV-1 in vivo, i.e., monocytes/macrophages and CD4+ T cells, express the costimulatory molecules CD80 (B7.1) and CD86 (B7.2). We investigated whether CD80 and CD86 are efficiently acquired by HIV-1, and if so, whether these host-encoded molecules can contribute to the virus life cycle. Here we provide the first evidence that the insertion of CD80 and CD86 into HIV-1 increases virus infectivity by facilitating the attachment and entry process due to interactions with their two natural ligands, CD28 and CTLA-4. Moreover, we demonstrate that NF-kappaB is induced by CD80- and CD86-bearing virions when they are combined with the engagement of the T-cell receptor/CD3 complex, an event that is inhibited upon surface expression of CTLA-4. Finally, both CD80 and CD86 were found to be efficiently incorporated into R5- and X4-tropic field strains of HIV-1 expanded in cytokine-treated macrophages. Thus, besides direct interactions between the virus envelope glycoproteins and cell surface constituents, such as CD4 and some specific chemokine coreceptors, HIV-1 may attach to target cells via interactions between cell-derived molecules incorporated into virions and their natural ligands. These findings support the theory that HIV-1-associated host proteins alter virus-host dynamics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163715      PMCID: PMC416533          DOI: 10.1128/JVI.78.12.6222-6232.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

2.  Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo.

Authors:  J A Mikovits; N C Lohrey; R Schulof; J Courtless; F W Ruscetti
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

3.  B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro.

Authors:  D M Sansom; N D Hall
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

4.  Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition.

Authors:  M Larkin; R A Childs; T J Matthews; S Thiel; T Mizuochi; A M Lawson; J S Savill; C Haslett; R Diaz; T Feizi
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

5.  The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions.

Authors:  T Wyss-Coray; D Mauri-Hellweg; K Baumann; F Bettens; R Grunow; W J Pichler
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

6.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression.

Authors:  N Nabavi; G J Freeman; A Gault; D Godfrey; L M Nadler; L H Glimcher
Journal:  Nature       Date:  1992-11-19       Impact factor: 49.962

8.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

9.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.

Authors:  P S Linsley; J L Greene; P Tan; J Bradshaw; J A Ledbetter; C Anasetti; N K Damle
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

10.  Functional expression of B7/BB1 on activated T lymphocytes.

Authors:  M Azuma; H Yssel; J H Phillips; H Spits; L L Lanier
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

View more
  15 in total

1.  Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.

Authors:  Lucas Chan; Darren Nesbeth; Taylor Mackey; Joanna Galea-Lauri; Joop Gäken; Francisco Martin; Mary Collins; Ghulam Mufti; Farzin Farzaneh; David Darling
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 2.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

Review 3.  Molecular determinants of the ratio of inert to infectious virus particles.

Authors:  P J Klasse
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

4.  Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.

Authors:  Geoffrey H Holm; Dana Gabuzda
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound.

Authors:  Michael J Corley; Alina P S Pang; Thomas A Rasmussen; Martin Tolstrup; Ole S Søgaard; Lishomwa C Ndhlovu
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

6.  Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins.

Authors:  Kei Sato; Jun Aoki; Naoko Misawa; Eriko Daikoku; Kouichi Sano; Yuetsu Tanaka; Yoshio Koyanagi
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 envelope gp120-induced partial T-cell receptor signaling creates an F-actin-depleted zone in the virological synapse.

Authors:  Gaia Vasiliver-Shamis; Michael W Cho; Catarina E Hioe; Michael L Dustin
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

8.  Efficient replication of human immunodeficiency virus type 1 in resting CD4+ T lymphocytes is induced by coculture with autologous dendritic cells in the absence of foreign antigens.

Authors:  Corinne Barat; Caroline Gilbert; Michel J Tremblay
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

9.  The nucleoside triphosphate diphosphohydrolase-1/CD39 is incorporated into human immunodeficiency type 1 particles, where it remains biologically active.

Authors:  Corinne Barat; Geneviève Martin; Adrien R Beaudoin; Jean Sévigny; Michel J Tremblay
Journal:  J Mol Biol       Date:  2007-05-10       Impact factor: 5.469

10.  Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion.

Authors:  Bharat K R Chaganty; Yang Lu; Songbo Qiu; Srinivas S Somanchi; Dean A Lee; Zhen Fan
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.